| 田东立,李芳梅,芦恩婷,等.铂耐药复发性卵巢癌诊治中国专家共识（2025年版）[J].肿瘤学杂志,2025,31(2):83-93. |
| 铂耐药复发性卵巢癌诊治中国专家共识（2025年版） |
| Chinese Expert Consensus on the Diagnosis and Treatment of Platinum-Resistant Recurrent Ovarian Cancer（Version 2025） |
| 投稿时间：2025-01-27 |
| DOI：10.11735/j.issn.1671-170X.2025.02.B001 |
|
 |
| 中文关键词: 卵巢肿瘤 铂 药物耐受性 复发 血管生成抑制剂 专家共识 |
| 英文关键词:ovarian neoplasms platinum drug tolerance recurrence angiogenesis inhibitors expert consensus |
| 基金项目:辽宁省重点研发项目（2024JH2/102500019）；2022年沈阳市科技计划（22-321-33-08）；沈阳市科技局2023年助力中国医科大学高质量发展专项（23-506-3-01-10） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘 要：在妇科恶性肿瘤中，卵巢癌的预后状况最为严峻，主要原因在于其治疗后具有较高的复发风险，多次复发会导致耐药风险升高。复发性卵巢癌分为铂敏感和铂耐药两类，治疗策略依赖于患者对铂类化疗的敏感性。对于铂敏感复发性卵巢癌患者再次使用以铂类为基础的化疗联合靶向治疗（如PARP抑制剂或贝伐珠单抗等）已证实能延长生存期。但铂耐药复发性卵巢癌患者的治疗存在极大的挑战，常规治疗药物的反应率和缓解率均普遍较低，因此常采用非铂类药物或新型治疗手段，如靶向治疗、免疫疗法和抗体药物偶联物等。通过个体生物标志物的检测及针对性治疗有望进一步优化复发性卵巢癌的治疗效果，提高患者的生存期和生活质量。 |
| 英文摘要: |
| Abstract： The prognosis of ovarian cancer is the most severe one of gynecological cancers， mainly due to its high risk of recurrence after treatment， multiple recurrences can lead to increase the risk of drug resistance. Recurrent ovarian cancer can be divided into two categories of platinum-sensitive and platinum-resistant， the treatment strategy depends on the patient’s response time to platinum-based chemotherapy. For platinum-sensitive recurrent patients， repeating the use of platinum-based chemotherapy combined with targeted therapy （such as PARP inhibitors or bevacizumab） has been proven to extend survival. But the treatment of platinum-resistant patients presents great challenges， the response rate and remission rate of conventional treatment drugs are generally low， so non-platinum drugs or novel treatment means， such as targeted therapy， immunotherapy and antibody-drug conjugates are often used. By detecting individual biomarkers and targeted treatment， it is expected to further optimize the treatment effect of recurrent ovarian cancer and improve the survival time and quality of life of patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |